Non-Opioid Depressants: Benzos, Z-Drugs, and the Ones You Didn't Know About
Prescribed to calm anxiety and sleep. Capable of producing some of the hardest withdrawals in medicine.
Body — 8 lenses: [Science: GABA-A positive allosteric modulators (benzos, Z-drugs), GHB at GHB receptor + GABA-B. Biology: sedation, anterograde amnesia, paradoxical disinhibition. Withdrawal: kindling effect, protracted symptoms, seizure risk. Psychology: chronic benzo dependence via therapeutic use; iatrogenic pathway; cognitive effects. Policy: Schedule IV (benzos, Z-drugs), II (barbiturates), I (GHB), but designer benzos (etizolam, flubromazolam) circulate as novel psychoactives. Trends: benzo Rx rising; designer benzo detection in overdose deaths; fentanyl-benzo co-use lethal combination. Social: the “mother’s little helper” legacy; TikTok-era anxiety prescribing. Treatment: slow taper (Ashton Manual), CBT for anxiety, flumazenil only for overdose. Harm reduction: NEVER mix with opioids/alcohol, test-strip availability for designer benzos, naloxone doesn’t reverse benzo respiratory depression.]
Sources Cited
- 01.A
- 02.Bhttps://www.benzoinfo.comBenzodiazepine Information Coalition
Filed Under
sciencebiologypsychologypolicytrendssocial-culturaltreatmentharm-reductionPeer-Reviewed Research
Keep up with the reporting.
One email each morning with the stories that put days like this in context.
Continue reading
More from this section
Psilocybin Lowered Inflammation Markers in Parkinson's Patients. Don't Let Anyone Tell You What That Proves.
A JAMA Psychiatry study reports lower inflammation markers in people with Parkinson's disease after psilocybin. It was small and had no control group. What it can and cannot tell clinicians.
Science & MedicineDoubling the THC Doesn't Double the High. So Why Is Everyone Selling It That Way?
A meta-analysis of 41 THC experiments finds that doubling the dose from 5 to 10 mg raised the self-reported high by about 15 percent and left anxiety unchanged. What it means for people who use, and for providers.
Science & MedicineTwo Postdocs Are Telling the DEA That Schedule I Is Not a Place to Park Uncertainty
Students for Sensible Drug Policy, two early-career scientists and MindState Design Labs asked the DEA for a hearing on placing five tryptamines in Schedule I. What the proposal covers, what it doesn't, and who it could hit first.